Diltiazem - Blue Note Pharmaceuticals
Alternative Names: BNP 32,762; DOV DiltiazemLatest Information Update: 06 Jan 2022
At a glance
- Originator DOV Pharmaceutical
- Developer Blue Note Pharmaceuticals
- Class Antihypertensives; Benzazepines; Ischaemic heart disorder therapies; Small molecules
- Mechanism of Action Calcium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Angina pectoris; Hypertension
Most Recent Events
- 22 Jul 2010 Euthymics Bioscience acquires DOV Pharmaceutical
- 24 Mar 2009 Phase-III clinical trials in Angina pectoris in USA (PO)
- 24 Mar 2009 Phase-III clinical trials in Hypertension in USA (PO)